Login to Your Account

GSK's Nucala gets nod as asthma add-on; Teva's drug up next

By Jennifer Boggs
Managing Editor

Thursday, November 5, 2015

The FDA added another drug to the asthma armamentarium, with the approval of Glaxosmithkline plc's Nucala as an add-on maintenance therapy for patients who have a history of severe asthma attacks despite being on treatment and who have an eosinophilic phenotype.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription